Gemcitabine plus vandetanib vs vandetanib
Serious adverse events · people with advanced biliary tract carcinomas
It is very uncertain whether gemcitabine plus vandetanib changes serious adverse events compared with vandetanib (very low certainty).
1 finding from 1 review
- Gemcitabine‐based chemotherapy for advanced biliary tract carcinomas 2018 · Cochrane Headline outcomes onlyRR 0.95 [0.52, 1.74]1 study · 117 participantsVery low